Abstract
Vesicular stomatitis virus-Ebola virus (VSV-EBOV) vaccine has been successfully used in ring vaccination approaches during EBOV disease outbreaks demonstrating its general benefit in short-term prophylactic vaccination, but actual proof of its benefit in true postexposure prophylaxis (PEP) for humans is missing. Animal studies have indicated PEP efficacy when VSV-EBOV was used within hours of lethal EBOV challenge. Here, we used a lower EBOV challenge dose and a combined intravenous and intramuscular VSV-EBOV administration to improve PEP efficacy in the rhesus macaque model. VSV-EBOV treatment 1 hour after EBOV challenge resulted in delayed disease progression but little benefit in outcome. Thus, we could not confirm previous results indicating questionable benefit of VSV-EBOV for EBOV PEP in a nonhuman primate model.
Original language | English (US) |
---|---|
Pages (from-to) | S721-S729 |
Journal | Journal of Infectious Diseases |
Volume | 228 |
DOIs | |
State | Published - Nov 15 2023 |
Keywords
- Ebola virus
- Ervebo
- VSV-EBOV
- administration route
- challenge dose
- postexposure prophylaxis
- rhesus macaque
ASJC Scopus subject areas
- General Medicine